SPRO — Spero Therapeutics, Inc.

Spero Therapeutics Q2 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $14.2 million for Q2 2025, up from $10.2 million in Q2 2024, primarily driven by collaboration revenue from GSK.
• R&D Expenses: $10.7 million, significantly reduced from $23.7 million in the prior year due to decreased clinical expenses related to the PIVOT-PO trial.
• G&A Expenses: Increased to $5.9 million from $5.5 million year-over-year, attributed to higher personnel and professional services costs.
• Net Loss: Reported at $1.7 million for Q2 2025, a substantial improvement from a net loss of $17.9 million in Q2 2024. Diluted net loss per share improved to $0.03 from $0.33.

2. Strategic Updates and Business Highlights:

• Tebipenem HBr: The Phase III PIVOT-PO trial for complicated urinary tract infections (cUTIs) met its primary endpoint and was stopped early for efficacy, indicating strong potential for approval.
• Regulatory Plans: GSK plans to file for FDA approval by year-end 2025, with potential FDA action anticipated in the second half of 2026. Spero could receive up to $351 million in contingent milestones from GSK.
• Cost Savings: Early trial termination has led to significant cost savings, extending Spero's cash runway into 2028.

3. Forward Guidance and Outlook:

• Cash Position: As of June 30, 2025, Spero reported $31.2 million in cash and cash equivalents, which, along with expected milestone payments, is projected to fund operations through 2028.
• Focus on Tebipenem: The company aims to prioritize funding for the regulatory process for Tebipenem HBr, which is seen as a key value driver.

4. Bad News, Challenges, or Points of Concern:

• SPR720 Program: The Phase IIa trial for SPR720 did not meet its primary endpoint, raising concerns about its future viability. Safety signals, including cases of hepatotoxicity, were noted.
• Market Competition: The potential for Tebipenem HBr to face competition from existing IV therapies and other emerging oral alternatives remains a consideration.

5. Notable Q&A Insights:

• Capital Allocation: Management emphasized that the primary focus will be on ensuring the successful regulatory process for Tebipenem HBr. Future capital allocation decisions will be made post-approval visibility.
• Long-term Strategy: The company is committed to advancing its pipeline while managing resources effectively to support the most promising candidates.

Overall, Spero Therapeutics demonstrated significant progress in its clinical programs and financial health, particularly with the positive outcomes from the PIVOT-PO trial, while also facing challenges with its SPR720 program. The focus remains on securing regulatory approval for Tebipenem HBr, which is positioned as a potential game-changer in the treatment of cUTIs.